Royal College of Physicians

Royal College of Physicians
11 St Andrews Place
Regent's Park
London NW1 4LE
Tel: +44 (0)20 3075 1560

www.rcplondon.ac.uk

Submitted via NICE Docs

15 October 2014

Dear Sir or Madam

Re: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (ID 695) - Appraisal Consultation Document (ACD)

The Royal College of Physicians (RCP) plays a leading role in the delivery of high quality patient care by setting standards of medical practice and promoting clinical excellence. We provide physicians in the United Kingdom and overseas with education, training and support throughout their careers. As an independent body representing over 30,000 Fellows and Members worldwide, we advise and work with government, the public, patients and other professions to improve health and healthcare.

The RCP is grateful for the opportunity to respond to the above ACD consultation. We wish to fully endorse the submissions made by the BSG and Crohn's and Colitis UK (CCUK). In addition, we would like to add a supporting statement from the UK IBD audit.

The UK IBD audit collects data on people with inflammatory bowel disease (Crohn's and Ulcerative colitis). Patients newly starting on biological therapies are included in the national audit. These drugs have a potentially positive impact, they are a vital part of treatment and if withdrawn could be detrimental to the quality of life of patients. It is likely the cost of these drugs will decrease with the imminent introduction of biosimilars.

Yours faithfully